Appropriate and inappropriate therapies of implantable cardioverter‑defibrillators
Authors:
David Kiss 1,2; Milan Kozák 1,2; Milan Sepši 1,2; Petr Kala 1,2
Authors‘ workplace:
Interní kardiologická klinika, Fakultní nemocnice Brno
1; Interní kardiologická klinika, Lékařská fakulta Masarykovy univerzity
2
Published in:
Vnitř Lék 2021; 67(7): 426-432
Category:
Review Articles
Overview
Implantable cardioverter-defibrillators (ICD) reduce mortality of patients with risk of sudden cardiac death in primary and secondary prevention. Patients with implanted ICD can receive appropriate and inappropriate therapies with different incidence in both indication groups. There are some factors which can predict the incidence of ICD therapies. In some cases higher incidence of ICD therapies could negatively impact quality of patients lives. As predictive factors for higher incidence of appropriate therapies are discussed: reduced left venctricular ejection fraction, body mass index, chronic renal failure and frequent hospitalization for acute decompensation of chronic heart failure. As predictive factors for higher incidence of inappropriate therapies are discussed supraventricular tachycardia in patients history and single-chamber implantable kardioverter- defibrillator. The article summarizes indication criteria, incidence, predictive factors and treatment of appropriate and inappropriate therapies.
Keywords:
sudden cardiac death – appropriate therapy – implantable cardioverter‑defibrillator – inappropriate therapy
Sources
1. Kozák M. [Therapy with implantable cardioverter‑defibrillators (ICD) in the early of third millenium]. Vnitr Lek 2010; 56(8): 860–864.
2. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure. N Engl J Med 2005; 352(3): 225–237. doi:10.1056/ NEJMoa043399
3. Priori SG, Blomström‑Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36(41): 2793–2867. doi:10.1093/eurheartj/ehv316
4. Sweeney MO, Wathen MS, Volosin K et al. Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial. Circulation 2005; 111(22): 2898–2905. doi:10.1161/ CIRCULATIONAHA.104.526673
5. Weeke P, Johansen JB, Jorgensen OD et al. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter‑defibrillators for primary prevention: data from the Danish ICD Register. Europace 2013; 15(8): 1150–1157. doi:10.1093/europace/eut017
6. Boulé S, Sémichon M, Guédon‑Moreau L et al. Long‑term outcome of implantable cardioverter–defibrillator implantation in secondary prevention of sudden cardiac death. Arch Cardiovasc Dis 2016; 109(10): 517–526. doi:10.1016/j.acvd.2016. 02. 008
7. Moss AJ, Hall WJ, Cannom DS et al. Cardiac‑Resynchronization Therapy for the Prevention of Heart‑Failure Events. N Engl J Med 2009; 361(14): 1329–1338. doi:10.1056/ NEJMoa0906431
8. Ruwald AC, Vinther M, Gislason GH et al. The impact of co‑morbidity burden on appropriate implantable cardioverter defibrillator therapy and all‑cause mortality: insight from Danish nationwide clinical registers: ICD implantation and co‑morbidities. Eur J Heart Fail 2017; 19(3): 377–386. doi:10.1002/ejhf.685
9. Greenlee RT, Go AS, Peterson PN et al. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter–Defibrillators in the Cardiovascular Research Network. J Am Heart Assoc 2018; 7(7). doi:10.1161/JAHA.117.008292
10. Providência R, Marijon E, Lambiase PD et al. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women–Data From a Multicenter French Registry. J Am Heart Assoc 2016; 5(2). doi:10.1161/JAHA.115.002756
11. Schaer B, Kühne M, Reichlin T, Osswald S, Sticherling C. Incidence of and predictors for appropriate implantable cardioverter‑defibrillator therapy in patients with a secondary preventive implantable cardioverter‑defibrillator indication. Europace 2016; 18(2): 227–231. doi:10.1093/europace/euv188
12. Sapp JL, Wells GA, Parkash R et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med 2016; 375(2): 111–121. doi:10.1056/NEJMoa1513614
13. Sweeney MO, Wathen MS, Volosin K et al. Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial. Circulation 2005; 111(22): 2898–2905. doi:10.1161/CIRCULATIONAHA. 104.526673
14. Tompkins CM, Mcnitt S, Polonsky B et al. Sex Differences in Inappropriate ICD Device Therapies: MADIT‑II and MADIT‑CRT: Sex Differences in Inappropriate ICD Device Therapies. J Cardiovasc Electrophysiol 2017; 28(1): 94–102. doi:10.1111/jce.13102
15. Ahmed I, Nelson WB, House CM, Zhu DW. Predictors of appropriate therapy in patients with implantable cardioverter‑defibrillator for primary prevention of sudden cardiac death. Heart Int 2010; 5(1): e4. doi:10.4081/hi.2010.e4
16. Wu KC, Wongvibulsin S, Tao S et al. Baseline and Dynamic Risk Predictors of Appropriate Implantable Cardioverter Defibrillator Therapy. J Am Heart Assoc 2020; 9(20). doi:10.1161/ JAHA.120.017002
17. Moss AJ, Schuger C, Beck CA et al. Reduction in Inappropriate Therapy and Mortality through ICD Programming. N Engl J Med 2012; 367(24): 2275–2283. doi:10.1056/NEJMoa1211107
18. Biffi M. ICD programming. Indian Heart J 2014; 66: S88–S100. doi:10.1016/j.ihj.2013. 11. 007
19. Schwab JO, Bonnemeier H, Kleemann T et al. Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study. Clin Res Cardiol 2015; 104(12):1021–1032. doi:10.1007/s00392-015-0870-z
20. Burger AL, Schmidinger H, Ristl R, Pezawas T. Appropriate and inappropriate therapy in patients with single- or multi‑chamber implantable cardioverter‑defibrillators. Hellenic J Cardiol. Published online April 2020:S1109966620300609. doi:10.1016/j.hjc.2020. 03. 001
21. Hu Z‑Y, Zhang J, Xu Z‑T et al. Efficiencies and Complications of Dual Chamber versus Single Chamber Implantable Cardioverter Defibrillators in Secondary Sudden Cardiac Death Prevention: A Meta‑analysis. Heart Lung Circ 2016; 25(2):148–154. doi:10.1016/j. hlc.2015. 07. 008
22. Kronborg MB, Johansen JB, Haarbo J et al. Association between implantable cardioverter‑defibrillator therapy and different lead positions in patients with cardiac resynchronization therapy. EP Eur 2018; 20(9): e133–e139. doi:10.1093/europace/eux296
23. Zarse M, Bogossian H, Lemke B. Elektrischer Sturm bei ICD‑Patienten: Prävention und Behandlung. Herzschrittmachertherapie Elektrophysiologie. 2014; 25(2): 66–72. doi:10.1007/ s00399-014-0307-9
24. Parkash R, Nault I, Rivard L et al. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease). Circ Arrhythm Electrophysiol. 2018; 11(1). doi:10.1161/CIRCEP.117.005663
25. Kuck K‑H, Schaumann A, Eckardt L et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. The Lancet 2010; 375(9708): 31–40. doi:10.1016/ S0140-6736(09)61755-4
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2021 Issue 7
Most read in this issue
- Hereditary hemorrhagic telangiectasia (Osler‑Weber‑Rendu syndrome) – Part II. Pharmacological therapy and international guidelines for the therapy 2020
- Appropriate and inappropriate therapies of implantable cardioverter‑defibrillators
- Metabolic and endocrine diseases – is our approach always rational?
- First zero contrast PCI guided by intracoronary ultrasound in the Czech Republic